Books and Book Chapters

    Lipidomics in Multi-Omics Studies

    Titz, B.; Lavrynenko, O.; Ivanov, N. V.

    Date published
    Mar 10, 2023
    DOI
    10.1002/9783527836512.ch23
    Published in
    Mass Spectrometry for Lipidomics: Methods and Applications
    Editors
    Holčapek, M.; Ekroos, K.
    Link to publication
    Topic
    Summary

    Lipidomics and integrative multi-omics methods are emerging rapidly. In this chapter, we highlight the role that lipidomics data can play in multi-omics studies. We exemplify how lipidomics data have contributed to insights in recent multi-omics studies. We describe specific considerations on the experimental methods and give an overview of relevant integrative computational analysis approaches. The experimental design must be adapted to the multi-omics context, and data analysis challenges must be considered. Finally, we summarize the great potential of lipidomics data in multi-omics and suggest ways in which the knowledge from such multimodal analysis sets can be further increased.

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.